Results 11 to 20 of about 177,431 (250)

Decreased Immunoglobulin G Core Fucosylation, A Player in Antibody-dependent Cell-mediated Cytotoxicity, is Associated with Autoimmune Thyroid Diseases. [PDF]

Mol Cell Proteomics, 2020
Martin TC, Šimurina M, Ząbczyńska M, Martinic Kavur M, Rydlewska M, Pezer M, Kozłowska K, Burri A, Vilaj M, Turek-Jabrocka R, Krnjajić-Tadijanović M, Trofimiuk-Müldner M, Ugrina I, Lityńska A, Hubalewska-Dydejczyk A, Trbojevic-Akmacic I, Lim EM, Walsh JP, Pocheć E, Spector TD, Wilson SG, Lauc G.   +21 more
europepmc   +2 more sources

The Contribution of IgG Glycosylation to Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Complement-Dependent Cytotoxicity (CDC) in Hashimoto's Thyroiditis: An in Vitro Model of Thyroid Autoimmunity. [PDF]

Biomolecules, 2020
Ząbczyńska M, Polak K, Kozłowska K, Sokołowski G, Pocheć E.   +4 more
europepmc   +2 more sources

An IL-15 Superagonist, ALT-803, Enhances Antibody-Dependent Cell-Mediated Cytotoxicity Elicited by the Monoclonal Antibody NEO-201 Against Human Carcinoma Cells. [PDF]

Cancer Biother Radiopharm, 2019
Fantini M, David JM, Wong HC, Annunziata CM, Arlen PM, Tsang KY.   +5 more
europepmc   +2 more sources

Harnessing the immunomodulatory effects of exercise to enhance the efficacy of monoclonal antibody therapies against B-cell haematological cancers: a narrative review

Frontiers in Oncology, 2023
Therapeutic monoclonal antibodies (mAbs) are standard care for many B-cell haematological cancers. The modes of action for these mAbs include: induction of cancer cell lysis by activating Fcγ-receptors on innate immune cells; opsonising target cells for ...
Harrison D. Collier-Bain, Frankie F. Brown, Frankie F. Brown, Adam J. Causer, Annabelle Emery, Rebecca Oliver, Rebecca Oliver, Sally Moore, James Murray, James E. Turner, James E. Turner, John P. Campbell   +11 more
doaj   +1 more source

Protease-Activation of Fc-Masked Therapeutic Antibodies to Alleviate Off-Tumor Cytotoxicity

Frontiers in Immunology, 2021
The interaction of the Fc region of therapeutic antibodies and antibody-drug conjugates with Fcγ receptors (FcγRs) can lead to unpredictable and severe side effects.
Adrian Elter, Desislava Yanakieva, Desislava Yanakieva, David Fiebig, Kerstin Hallstein, Stefan Becker, Ulrich Betz, Harald Kolmar   +7 more
doaj   +1 more source

The Early Antibody-Dependent Cell-Mediated Cytotoxicity Response Is Associated With Lower Viral Set Point in Individuals With Primary HIV Infection. [PDF]

Front Immunol, 2018
Chen X, Lin M, Qian S, Zhang Z, Fu Y, Xu J, Han X, Ding H, Dong T, Shang H, Jiang Y.   +10 more
europepmc   +2 more sources

Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells

Frontiers in Immunology, 2020
Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38, a protein highly expressed on hematological malignant cells, including those in multiple myeloma (MM).
Chen Zhu, Zhili Song, Anlai Wang, Srimathi Srinivasan, Guang Yang, Rita Greco, Joachim Theilhaber, Elvis Shehu, Lan Wu, Zhi-Yong Yang, Wilfried Passe-Coutrin, Alain Fournier, Yu-Tzu Tai, Kenneth C. Anderson, Dmitri Wiederschain, Keith Bahjat, Francisco J. Adrián, Marielle Chiron   +17 more
doaj   +1 more source

Different IVIG glycoforms affect in vitro inhibition of anti-ganglioside antibody-mediated complement deposition. [PDF]

PLoS ONE, 2014
Intravenous immunoglobulin (IVIG) is the first line treatment for Guillain-Barré syndrome and multifocal motor neuropathy, which are caused by anti-ganglioside antibody-mediated complement-dependent cytotoxicity.
Makoto Sudo, Yoshiki Yamaguchi, Peter J Späth, Kana Matsumoto-Morita, Benjamin K Ong, Nortina Shahrizaila, Nobuhiro Yuki   +6 more
doaj   +1 more source

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

Haematologica, 2011
Background In our efforts to develop novel effective treatment regimens for multiple myeloma we evaluated the potential benefits of combining the immunomodulatory drug lenalidomide with daratumumab.
Michael. S. van der Veer, Michel de Weers, Berris van Kessel, Joost M. Bakker, Shulamiet Wittebol, Paul W.H.I. Parren, Henk M. Lokhorst, Tuna Mutis   +7 more
doaj   +1 more source

Non-Coated Rituximab Induces Highly Cytotoxic Natural Killer Cells From Peripheral Blood Mononuclear Cells via Autologous B Cells

Frontiers in Immunology, 2021
Natural killer (NK) cells are becoming valuable tools for cancer therapy because of their cytotoxicity against tumor cells without prior sensitization and their involvement in graft-versus-host disease; however, it is difficult to obtain highly cytotoxic
Chao Niu, Yongchong Chen, Min Li, Shan Zhu, Lei Zhou, Dongsheng Xu, Zhaozhi Li, Jianting Xu, Wei Li, Yufeng Wang, Jiuwei Cui   +10 more
doaj   +1 more source